[go: up one dir, main page]

GB202404021D0 - Cell-based neurotoxin assay - Google Patents

Cell-based neurotoxin assay

Info

Publication number
GB202404021D0
GB202404021D0 GBGB2404021.4A GB202404021A GB202404021D0 GB 202404021 D0 GB202404021 D0 GB 202404021D0 GB 202404021 A GB202404021 A GB 202404021A GB 202404021 D0 GB202404021 D0 GB 202404021D0
Authority
GB
United Kingdom
Prior art keywords
cell
assay
neurotoxin assay
based neurotoxin
neurotoxin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2404021.4A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ipsen Biopharm Ltd
Original Assignee
Ipsen Biopharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Biopharm Ltd filed Critical Ipsen Biopharm Ltd
Priority to GBGB2404021.4A priority Critical patent/GB202404021D0/en
Publication of GB202404021D0 publication Critical patent/GB202404021D0/en
Priority to PCT/GB2025/050596 priority patent/WO2025196445A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/66—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving luciferase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/33—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Clostridium (G)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
GBGB2404021.4A 2024-03-20 2024-03-20 Cell-based neurotoxin assay Ceased GB202404021D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB2404021.4A GB202404021D0 (en) 2024-03-20 2024-03-20 Cell-based neurotoxin assay
PCT/GB2025/050596 WO2025196445A1 (en) 2024-03-20 2025-03-20 Cell-based neurotoxin assay

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2404021.4A GB202404021D0 (en) 2024-03-20 2024-03-20 Cell-based neurotoxin assay

Publications (1)

Publication Number Publication Date
GB202404021D0 true GB202404021D0 (en) 2024-05-01

Family

ID=90826200

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2404021.4A Ceased GB202404021D0 (en) 2024-03-20 2024-03-20 Cell-based neurotoxin assay

Country Status (2)

Country Link
GB (1) GB202404021D0 (en)
WO (1) WO2025196445A1 (en)

Citations (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992006204A1 (en) 1990-09-28 1992-04-16 Ixsys, Inc. Surface expression libraries of heteromeric receptors
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
WO2006027207A1 (en) 2004-09-06 2006-03-16 Toxogen Gmbh Transport protein which is used to introduce chemical compounds into nerve cells
WO2006114308A2 (en) 2005-04-26 2006-11-02 Toxogen Gmbh Carrier for targeting nerve cells
US20070166332A1 (en) 2005-09-19 2007-07-19 Allergan, Inc. Clostridial Toxin Activatable Clostridial Toxins
WO2008008803A2 (en) 2006-07-11 2008-01-17 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells
WO2008008805A2 (en) 2006-07-11 2008-01-17 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells
US8071110B2 (en) 1999-08-25 2011-12-06 Allergan, Inc. Activatable clostridial toxins
EP2635582A1 (en) 2010-11-02 2013-09-11 Promega Corporation Novel coelenterazine substrates and methods of use
US8557970B2 (en) 2009-05-01 2013-10-15 Promega Corporation Synthetic Oplophorus luciferases with enhanced light output
WO2013180799A1 (en) 2012-05-30 2013-12-05 President And Fellows Of Harvard College Engineered botulinum neurotoxin
EP2677029A2 (en) 2011-05-19 2013-12-25 Syntaxin Limited Methods for the manufacture of proteolytically processed polypeptides
WO2014079495A1 (en) 2012-11-21 2014-05-30 Syntaxin Limited Methods for the manufacture of proteolytically processed polypeptides
WO2015004461A1 (en) 2013-07-09 2015-01-15 Syntaxin Limited Cationic neurotoxins
WO2016110662A1 (en) 2015-01-09 2016-07-14 Ipsen Bioinnovation Limited Cationic neurotoxins
WO2016154534A1 (en) 2015-03-26 2016-09-29 President And Fellows Of Harvard College Engineered botulinum neurotoxin
WO2017191315A1 (en) 2016-05-05 2017-11-09 Ipsen Biopharm Limited Chimeric neurotoxins
WO2018009903A2 (en) 2016-07-08 2018-01-11 Children's Medical Center Corporation A novel botulinum neurotoxin and its derivatives
WO2018060351A1 (en) 2016-09-29 2018-04-05 Ipsen Biopharm Limited Hybrid neurotoxins
WO2018075783A2 (en) 2016-10-20 2018-04-26 President And Fellows Of Harvard College In vitro and cell based assays for measuring the activity of botulinum neurotoxins
WO2020065336A1 (en) 2018-09-28 2020-04-02 Ipsen Biopharm Limited Clostridial neurotoxins comprising an exogenous activation loop

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3263710A1 (en) 2016-07-01 2018-01-03 Ipsen Biopharm Limited Production of activated clostridial neurotoxins
AR119109A1 (en) * 2019-06-07 2021-11-24 Synaptic Res Llc GENETICALLY MANIPULATED CELLS
AU2020330755A1 (en) * 2019-08-13 2022-03-03 Ipsen Biopharm Limited Cells highly sensitive to clostridial neurotoxin
GB202015618D0 (en) 2020-10-01 2020-11-18 Ipsen Biopharm Ltd Method for producing beta-trypsin
GB202213479D0 (en) * 2022-09-14 2022-10-26 Ipsen Biopharm Ltd Cell-free clostridial neurotoxin assays

Patent Citations (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
WO1992006204A1 (en) 1990-09-28 1992-04-16 Ixsys, Inc. Surface expression libraries of heteromeric receptors
US8071110B2 (en) 1999-08-25 2011-12-06 Allergan, Inc. Activatable clostridial toxins
WO2006027207A1 (en) 2004-09-06 2006-03-16 Toxogen Gmbh Transport protein which is used to introduce chemical compounds into nerve cells
WO2006114308A2 (en) 2005-04-26 2006-11-02 Toxogen Gmbh Carrier for targeting nerve cells
US20070166332A1 (en) 2005-09-19 2007-07-19 Allergan, Inc. Clostridial Toxin Activatable Clostridial Toxins
WO2008008803A2 (en) 2006-07-11 2008-01-17 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells
WO2008008805A2 (en) 2006-07-11 2008-01-17 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells
US8557970B2 (en) 2009-05-01 2013-10-15 Promega Corporation Synthetic Oplophorus luciferases with enhanced light output
EP2635582A1 (en) 2010-11-02 2013-09-11 Promega Corporation Novel coelenterazine substrates and methods of use
EP2677029A2 (en) 2011-05-19 2013-12-25 Syntaxin Limited Methods for the manufacture of proteolytically processed polypeptides
WO2013180799A1 (en) 2012-05-30 2013-12-05 President And Fellows Of Harvard College Engineered botulinum neurotoxin
WO2014079495A1 (en) 2012-11-21 2014-05-30 Syntaxin Limited Methods for the manufacture of proteolytically processed polypeptides
WO2014080206A1 (en) 2012-11-21 2014-05-30 Syntaxin Limited Methods for the manufacture of proteolytically processed polypeptides
WO2015004461A1 (en) 2013-07-09 2015-01-15 Syntaxin Limited Cationic neurotoxins
WO2016110662A1 (en) 2015-01-09 2016-07-14 Ipsen Bioinnovation Limited Cationic neurotoxins
WO2016154534A1 (en) 2015-03-26 2016-09-29 President And Fellows Of Harvard College Engineered botulinum neurotoxin
WO2017191315A1 (en) 2016-05-05 2017-11-09 Ipsen Biopharm Limited Chimeric neurotoxins
WO2018009903A2 (en) 2016-07-08 2018-01-11 Children's Medical Center Corporation A novel botulinum neurotoxin and its derivatives
WO2018060351A1 (en) 2016-09-29 2018-04-05 Ipsen Biopharm Limited Hybrid neurotoxins
WO2018075783A2 (en) 2016-10-20 2018-04-26 President And Fellows Of Harvard College In vitro and cell based assays for measuring the activity of botulinum neurotoxins
WO2020065336A1 (en) 2018-09-28 2020-04-02 Ipsen Biopharm Limited Clostridial neurotoxins comprising an exogenous activation loop

Non-Patent Citations (47)

* Cited by examiner, † Cited by third party
Title
"NCBI", Database accession no. NP_112253 .1
"UniProt", Database accession no. P04958
ALTSCHUL ET AL., BULL. MATH. BIO., vol. 48, 1986, pages 603 - 16
BENSON, MARC A. ET AL.: "Unique ganglioside recognition strategies for clostridial neurotoxins.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 286, no. 39, 2011, pages 34015 - 34022, XP055485185, DOI: 10.1074/jbc.M111.272054
BOTTENSTEINSATO, PNAS, vol. 76, 1979, pages 514 - 517
BOWIESAUER, PROC. NATL. ACAD. SCI. USA, vol. 86, 1989, pages 2152 - 6
BREWERCOTMAN, BRAIN RES., vol. 494, 1989, pages 65 - 74
C. E. LAWRENCE ET AL.: "Detecting Subtle Sequence Signals: A Gibbs Sampling Strategy for Multiple Alignment", SCIENCE, vol. 262, no. 5131, 1993, pages 208 - 214, XP001152872, DOI: 10.1126/science.8211139
CHEN ET AL., J. NEUROSCI. METHODS, vol. 171, no. 2, 2008, pages 239 - 247
CHUNG ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 10145 - 9
CHUNG ET AL., SCIENCE, vol. 259, 1993, pages 806 - 9
CRAIG ET AL., BIOCHEM J, vol. 276, 1991, pages 637 - 641
CUNNINGHAMWELLS, SCIENCE, vol. 244, 1989, pages 1081 - 5
DE VOS ET AL., SCIENCE, vol. 255, 1992, pages 306 - 12
DERBYSHIRE ET AL., GENE, vol. 46, 1986, pages 145
ELLMAN ET AL., METHODS ENZYMOL., vol. 202, 1991, pages 301
ERIC DEPIEREUXERNEST FEYTMANS: "Match-Box: A Fundamentally New Algorithm for the Simultaneous Alignment of Several Protein Sequences", CABIOS, vol. 8, no. 5, 1992, pages 501 - 509
HALEMARHAM: "THE HARPER COLLINS DICTIONARY OF BIOLOGY", 1991, HARPER PERENNIAL
HALPERN J, J. BIOL. CHEM., vol. 268, no. 15, 1993, pages 11188 - 11192
HENIKOFF, PROC. NATL. ACAD. SCI. USA, vol. 89, 1992, pages 10915 - 19
HERREROS J, BIOCHEM. J., vol. 347, 2000, pages 199 - 204
HONG ET AL., JOURNAL OF BIOMOLECULAR SCREENING, vol. 21, no. 1, 2016, pages 65 - 73
HONG ET AL., TOXICOLOGICAL SCIENCES, vol. 134, no. 1, 2013, pages 64 - 72
IVO VAN WALLE ET AL.: "Align-M -A New Algorithm for Multiple Alignment of Highly Divergent Sequences", BIOINFORMATICS, vol. 20, no. 9, 2004, pages 1428 - 1435
JULIE D. THOMPSON ET AL.: "CLUSTAL W: Improving the Sensitivity of Progressive Multiple Sequence Alignment Through Sequence Weighting, Position- Specific Gap Penalties and Weight Matrix Choice", NUCLEIC ACIDS RESEARCH, vol. 22, no. 22, 1994, pages 4673 - 4680, XP002956304
KNAPP, AM. CRYST. ASSOC. ABSTRACT PAPERS, vol. 25, 1998, pages 90
KOIDE ET AL., BIOCHEM., vol. 33, 1994, pages 7470 - 6
KROKEN, ABBY R. ET AL.: "Novel ganglioside-mediated entry of botulinum neurotoxin serotype D into neurons", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 286, no. 30, 2011, pages 26828 - 26837, XP055190569, DOI: 10.1074/jbc.M111.254086
LACEY DB, NAT. STRUCT. BIOL., vol. 5, 1998, pages 898 - 902
LAM, KWOK-HO ET AL.: "Diverse binding modes, same goal: The receptor recognition mechanism of botulinum neurotoxin", PROGRESS IN BIOPHYSICS AND MOLECULAR BIOLOGY, vol. 117, no. 2, 2015, pages 225 - 231, XP029586798, DOI: 10.1016/j.pbiomolbio.2015.02.004
LEDEEN, ROBERT W.GUSHENG WU.: "The multi-tasked life of GM1 ganglioside, a true factotum of nature.", TRENDS IN BIOCHEMICAL SCIENCES, vol. 40, no. 7, 2015, pages 407 - 418, XP002768079, DOI: 10.1016/j.tibs.2015.04.005
LOWMAN ET AL., BIOCHEM., vol. 30, 1991, pages 10832 - 7
NER ET AL., DNA, vol. 7, 1988, pages 127
OSAMU GOTOH: "Significant Improvement in Accuracy of Multiple Protein. Sequence Alignments by Iterative Refinement as Assessed by Reference to Structural Alignments", J. MOL. BIOL., vol. 264, no. 4, 1996, pages 823 - 838
REIDHAAR-OLSONSAUER, SCIENCE, vol. 241, 1988, pages 53 - 7
ROBERTSON ET AL., J. AM. CHEM. SOC., vol. 113, 1991, pages 2722
RUMMEL A, MOL. MICROBIOL., vol. 51, no. 3, 2004, pages 631 - 643
RUMMEL A, PNAS, vol. 104, 2007, pages 359 - 364
SESARDIC ET AL., BIOLOGICALS, vol. 31, no. 4, 2003, pages 265 - 276
SESARDIC ET AL., PHARMACOL TOXICOL, vol. 78, no. 5, 1996, pages 283 - 8
SINGLETON ET AL.: "DICTIONARY OF MICROBIOLOGY AND MOLECULAR BIOLOGY", 1994, JOHN WILEY AND SONS
SMITH ET AL., J. MOL. BIOL., vol. 224, 1992, pages 899 - 904
SWAMINATHANESWARAMOORTHY, NAT. STRUCT. BIOL., vol. 7, 2000, pages 1751 - 1759
TURCATTI ET AL., J. BIOL. CHEM., vol. 271, 1996, pages 19991 - 8
UMLAND TC, NAT. STRUCT. BIOL., vol. 4, 1997, pages 788 - 792
WLODAVER ET AL., FEBS LETT., vol. 309, 1992, pages 59 - 64
WYNNRICHARDS, PROTEIN SCI., vol. 2, 1993, pages 395 - 403

Also Published As

Publication number Publication date
WO2025196445A1 (en) 2025-09-25

Similar Documents

Publication Publication Date Title
EP4211234A4 (en) BASE-EDITING ENZYMES
DE602006018288D1 (en) ELASTOMER STRUCTURES
EP4426826A4 (en) BASE-EDITING ENZYMES
GB202404021D0 (en) Cell-based neurotoxin assay
GB202203276D0 (en) Assay
GB202418482D0 (en) Microfluidic enzyme assays
GB202409562D0 (en) Assay
GB202404073D0 (en) Bigh3m-n assay
GB202309589D0 (en) Microfluidic enzyme assays
SG11202102111SA (en) Cell-based clostridal neurotoxin assays
IL316443A (en) Cell based assays for botulinum neurotoxin
GB202411203D0 (en) Enzyme
GB202416416D0 (en) Liver assay
GB202307576D0 (en) C3a1-hne assay
GB202410791D0 (en) Protein expression reagents
GB202407052D0 (en) Protein expression reagents
GB202501991D0 (en) Thermofunctional enzymes
GB202501881D0 (en) Thermofunctional enzymes
GB202417669D0 (en) Multiplex assay
GB202218370D0 (en) Enzyme
GB202315935D0 (en) Novel enzymes
GB202509632D0 (en) Biosensor
GB202218069D0 (en) Enzymes
GB202213127D0 (en) Antibody assay
GB202209866D0 (en) Cross linked collagen type v assay

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)